Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNT-01 in idiopathic triglyceride deposit cardiomyovasculopathy
jRCT2051210177Phase 3Completed
- Sponsor
- TOA EIYO
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tricaprin in idiopathic triglyceride deposit cardiomyovasculopathy (I-TGCV) (2 arms), sponsored by TOA EIYO. Primary endpoint: major adverse cardiovascular events. Started Mar 2022; status: completed.
02
Drugs
tricaprin
03
Conditions
idiopathic triglyceride deposit cardiomyovasculopathy (I-TGCV)
Beyond the preview
Go deeper on jRCT2051210177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210177.